KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Change in Receivables (2016 - 2025)

Bristol Myers Squibb (BMY) has disclosed Change in Receivables for 17 consecutive years, with -$19.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Receivables rose 86.71% to -$19.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $295.0 million, a 211.74% increase, with the full-year FY2025 number at $295.0 million, up 211.74% from a year prior.
  • Change in Receivables was -$19.0 million for Q4 2025 at Bristol Myers Squibb, up from -$155.0 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $1.0 billion in Q2 2024 to a low of -$786.0 million in Q1 2022.
  • A 5-year average of $137.2 million and a median of $137.0 million in 2021 define the central range for Change in Receivables.
  • Peak YoY movement for Change in Receivables: crashed 1073.13% in 2022, then soared 1467.69% in 2024.
  • Bristol Myers Squibb's Change in Receivables stood at $168.0 million in 2021, then plummeted by 36.9% to $106.0 million in 2022, then surged by 379.25% to $508.0 million in 2023, then crashed by 128.15% to -$143.0 million in 2024, then soared by 86.71% to -$19.0 million in 2025.
  • Per Business Quant, the three most recent readings for BMY's Change in Receivables are -$19.0 million (Q4 2025), -$155.0 million (Q3 2025), and $484.0 million (Q2 2025).